[Form 4] Marsh & McLennan Companies, Inc. Insider Trading Activity
Marsh & McLennan Companies director Deborah C. Hopkins reported receipt of restricted stock units under the company's Directors Stock Compensation Plan that convert 1-for-1 into common stock. The transaction dated 08/15/2025 shows 85.08 underlying shares (acquired with dividend equivalents) and reports 19,752.73 shares beneficially owned following the transaction on a direct basis. The filing was executed by an attorney-in-fact on 08/18/2025. No exercise price or derivative expiration applies because these are restricted stock units that convert to common stock.
La direttrice di Marsh & McLennan Companies, Deborah C. Hopkins, ha dichiarato di aver ricevuto unit脿 azionarie vincolate ai sensi del piano di compensazione azionaria per amministratori della societ脿, che si convertono 1 a 1 in azioni ordinarie. La transazione datata 08/15/2025 indica 85.08 azioni sottostanti (acquisite con equivalenti dividendo) e segnala la detenzione effettiva di 19,752.73 azioni dopo la transazione su base diretta. Il deposito 猫 stato eseguito per procura da un avvocato il 08/18/2025. Non si applica alcun prezzo di esercizio n茅 scadenza di derivati poich茅 si tratta di unit脿 azionarie vincolate che si convertono in azioni ordinarie.
La directora de Marsh & McLennan Companies, Deborah C. Hopkins, inform贸 la recepci贸n de unidades restringidas de acciones bajo el Plan de Compensaci贸n en Acciones para Directores de la compa帽铆a, que se convierten 1 a 1 en acciones ordinarias. La transacci贸n con fecha 08/15/2025 muestra 85.08 acciones subyacentes (adquiridas con equivalentes de dividendo) y reporta la titularidad beneficiaria de 19,752.73 acciones tras la transacci贸n en base directa. La presentaci贸n fue realizada por un apoderado el 08/18/2025. No aplica precio de ejercicio ni vencimiento de derivados porque se trata de unidades restringidas que se convierten en acciones ordinarias.
Marsh & McLennan Companies 鞚挫偓 Deborah C. Hopkins電� 鞚� 須岇偓鞚� 鞚挫偓 欤检嫕 氤挫儊 瓿勴殟鞐� 霐半ジ 鞝滍暅攵� 欤检嫕 雼渼毳� 靾橂牴頄堨潓鞚� 氤搓碃頄堨溂氅�, 頃措嫻 雼渼電� 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅╇媹雼�. 08/15/2025鞛� 瓯半灅電� 氚半嫻 霌标皜毳� 韽暔頃� 85.08欤检潣 旮办磮 欤检嫕鞚� 響滌嫓頃橂┌, 瓯半灅 頉� 歆侅为 氤挫湢 旮办鞙茧 19,752.73欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃╇媹雼�. 鞝滌稖鞚� 08/18/2025鞐� 雽�毽澑鞚� 靾橅枆頄堨姷雼堧嫟. 鞚措姅 氤错喌欤茧 鞝勴櫂霅橂姅 鞝滍暅攵� 欤检嫕 雼渼鞚措瘈搿� 頄夓偓臧�雮� 韺岇儩靸來拡 毵岆電� 鞝侅毄霅橃 鞎婌姷雼堧嫟.
La administratrice de Marsh & McLennan Companies, Deborah C. Hopkins, a d茅clar茅 avoir re莽u des unit茅s d'actions restreintes dans le cadre du plan de r茅mun茅ration en actions des administrateurs de la soci茅t茅, lesquelles se convertissent 脿 raison de 1 pour 1 en actions ordinaires. La transaction dat茅e du 08/15/2025 indique 85.08 actions sous-jacentes (acquises avec des 茅quivalents de dividendes) et fait 茅tat d'une d茅tention b茅n茅ficiaire de 19,752.73 actions apr猫s la transaction sur une base directe. Le d茅p么t a 茅t茅 effectu茅 par un mandataire le 08/18/2025. Aucun prix d'exercice ni 茅ch茅ance de d茅riv茅s ne s'applique, car il s'agit d'unit茅s d'actions restreintes qui se convertissent en actions ordinaires.
Die Direktorin von Marsh & McLennan Companies, Deborah C. Hopkins, meldete den Erhalt von Restricted Stock Units im Rahmen des Directors Stock Compensation Plan des Unternehmens, die 1:1 in Stammaktien umgewandelt werden. Die Transaktion vom 08/15/2025 weist 85.08 zugrunde liegende Aktien aus (erworben mit Dividenden盲quivalenten) und meldet nach der Transaktion einen wirtschaftlichen Besitz von 19,752.73 Aktien auf direkter Basis. Die Einreichung wurde am 08/18/2025 durch einen Bevollm盲chtigten vorgenommen. Ein Aus眉bungspreis oder eine Laufzeit f眉r Derivate entf盲llt, da es sich um Restricted Stock Units handelt, die in Stammaktien umgewandelt werden.
- None.
- None.
Insights
TL;DR Director received a routine grant of RSUs converting to 85.08 shares; beneficial ownership now 19,752.73 shares.
This Form 4 documents a standard director compensation event under the Directors Stock Compensation Plan. The 85.08 restricted stock units were credited with dividend equivalents and convert 1-for-1 into common stock, consistent with the plan's mechanics. The incremental size of the grant is small relative to the total reported beneficial ownership, suggesting this is a routine, non-material equity compensation entry rather than a corporate governance or control signal.
TL;DR Routine director equity award; filing aligns with disclosure obligations and uses an attorney-in-fact signature.
The filing shows proper reporting of a director stock compensation event, including the use of dividend equivalents to acquire RSUs. The signature by an attorney-in-fact and the clear explanation that the RSUs convert 1-for-1 to common stock indicate standard administrative handling. There are no indications of accelerated vesting, sales, or unusual derivatives activity that would raise governance concerns.
La direttrice di Marsh & McLennan Companies, Deborah C. Hopkins, ha dichiarato di aver ricevuto unit脿 azionarie vincolate ai sensi del piano di compensazione azionaria per amministratori della societ脿, che si convertono 1 a 1 in azioni ordinarie. La transazione datata 08/15/2025 indica 85.08 azioni sottostanti (acquisite con equivalenti dividendo) e segnala la detenzione effettiva di 19,752.73 azioni dopo la transazione su base diretta. Il deposito 猫 stato eseguito per procura da un avvocato il 08/18/2025. Non si applica alcun prezzo di esercizio n茅 scadenza di derivati poich茅 si tratta di unit脿 azionarie vincolate che si convertono in azioni ordinarie.
La directora de Marsh & McLennan Companies, Deborah C. Hopkins, inform贸 la recepci贸n de unidades restringidas de acciones bajo el Plan de Compensaci贸n en Acciones para Directores de la compa帽铆a, que se convierten 1 a 1 en acciones ordinarias. La transacci贸n con fecha 08/15/2025 muestra 85.08 acciones subyacentes (adquiridas con equivalentes de dividendo) y reporta la titularidad beneficiaria de 19,752.73 acciones tras la transacci贸n en base directa. La presentaci贸n fue realizada por un apoderado el 08/18/2025. No aplica precio de ejercicio ni vencimiento de derivados porque se trata de unidades restringidas que se convierten en acciones ordinarias.
Marsh & McLennan Companies 鞚挫偓 Deborah C. Hopkins電� 鞚� 須岇偓鞚� 鞚挫偓 欤检嫕 氤挫儊 瓿勴殟鞐� 霐半ジ 鞝滍暅攵� 欤检嫕 雼渼毳� 靾橂牴頄堨潓鞚� 氤搓碃頄堨溂氅�, 頃措嫻 雼渼電� 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅╇媹雼�. 08/15/2025鞛� 瓯半灅電� 氚半嫻 霌标皜毳� 韽暔頃� 85.08欤检潣 旮办磮 欤检嫕鞚� 響滌嫓頃橂┌, 瓯半灅 頉� 歆侅为 氤挫湢 旮办鞙茧 19,752.73欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃╇媹雼�. 鞝滌稖鞚� 08/18/2025鞐� 雽�毽澑鞚� 靾橅枆頄堨姷雼堧嫟. 鞚措姅 氤错喌欤茧 鞝勴櫂霅橂姅 鞝滍暅攵� 欤检嫕 雼渼鞚措瘈搿� 頄夓偓臧�雮� 韺岇儩靸來拡 毵岆電� 鞝侅毄霅橃 鞎婌姷雼堧嫟.
La administratrice de Marsh & McLennan Companies, Deborah C. Hopkins, a d茅clar茅 avoir re莽u des unit茅s d'actions restreintes dans le cadre du plan de r茅mun茅ration en actions des administrateurs de la soci茅t茅, lesquelles se convertissent 脿 raison de 1 pour 1 en actions ordinaires. La transaction dat茅e du 08/15/2025 indique 85.08 actions sous-jacentes (acquises avec des 茅quivalents de dividendes) et fait 茅tat d'une d茅tention b茅n茅ficiaire de 19,752.73 actions apr猫s la transaction sur une base directe. Le d茅p么t a 茅t茅 effectu茅 par un mandataire le 08/18/2025. Aucun prix d'exercice ni 茅ch茅ance de d茅riv茅s ne s'applique, car il s'agit d'unit茅s d'actions restreintes qui se convertissent en actions ordinaires.
Die Direktorin von Marsh & McLennan Companies, Deborah C. Hopkins, meldete den Erhalt von Restricted Stock Units im Rahmen des Directors Stock Compensation Plan des Unternehmens, die 1:1 in Stammaktien umgewandelt werden. Die Transaktion vom 08/15/2025 weist 85.08 zugrunde liegende Aktien aus (erworben mit Dividenden盲quivalenten) und meldet nach der Transaktion einen wirtschaftlichen Besitz von 19,752.73 Aktien auf direkter Basis. Die Einreichung wurde am 08/18/2025 durch einen Bevollm盲chtigten vorgenommen. Ein Aus眉bungspreis oder eine Laufzeit f眉r Derivate entf盲llt, da es sich um Restricted Stock Units handelt, die in Stammaktien umgewandelt werden.
FAQ
What did MMC director Deborah C. Hopkins report on Form 4?
How many MMC shares does Deborah C. Hopkins beneficially own after the transaction?
When was the transaction and who signed the Form 4?
Were the RSUs acquired with dividend equivalents or purchased outright?
Does this Form 4 involve exercised options or derivative securities?
